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Introduction: Mesenchymal status is related to “inherent resis-
tance” to gefitinib or erlotinib in non-small cell lung cancer without
epidermal growth factor receptor (EGFR) mutations. In addition, a
recent report showed that the epithelial to mesenchymal transition
(EMT) plays a role in acquired resistance to gefitinib in A549 cells,
which harbor a KRAS mutation. However, recent clinical studies
revealed that gefitinib or erlotinib are highly effective in the treat-
ment of non-small cell lung cancer with EGFR mutations.
Methods: We developed resistant cells (HCC4006ER) from erlo-
tinib-sensitive HCC4006 cells harboring an EGFR deletion mutation
by chronic exposure to increasing concentrations of erlotinib. Ac-
quired resistance mechanisms of HCC4006ER cells were analyzed.
Results: Neither known resistance mechanisms nor novel molecules
that may confer erlotinib resistance were identified using candidate
or comprehensive analyses. In addition, HCC4006ER cells lost
dependency for EGFR. However, we found that HCC4006ER cells
acquired a mesenchymal phenotype and exhibited down-regulation
of E-cadherin expression (2.7  103 times compared with parental
cells). We also found that the histone deacetylase inhibitor, MS-275,
restored E-cadherin expression and moderate sensitivity to erlotinib
in HCC4006ER cells, on the other hand, transforming growth factor
beta, an inducer of EMT, led to moderate erlotinib resistance in
HCC4006 parental cells.
Conclusions: This is the first report of a relationship between EMT
and erlotinib acquired resistance in an erlotinib sensitive EGFR-
mutant lung cancer cell line. Our results indicate that it would be
important to consider the influence of EMT in the development of
treatments against acquired resistance to gefitinib or erlotinib.
Key Words: Acquired resistance, Erlotinib, Epithelial to mesenchy-
mal transition, Epidermal growth factor receptor gene mutation.
(J Thorac Oncol. 2011;6: 1152–1161)
Somatic mutations in the epidermal growth factor receptor(EGFR) gene are associated with significant clinical re-
sponses to orally available EGFR tyrosine kinase inhibitors
(TKIs) in patients with non-small cell lung cancer (NSCLC).
Although approximately 70 to 80% of the patients harboring
EGFR mutations respond to these drugs,1–4 acquired resis-
tance develops in almost all patients, which limits the
improvement of the outcomes of patients. EGFR secondary
mutations that cause drug-binding deficiency or activation
of alternative survival pathways have been reported as part
of the molecular mechanisms underlying these acquired
resistances.5–10
Mesenchymal status is related with “inherent resis-
tance” to gefitinib or erlotinib in in vitro models,11–14 in
xenograft models,11,14 and in clinical cases13 of NSCLC.
These reports provide a reason why some NSCLC cells
without EGFR mutations have moderate sensitivity to ge-
fitinib or erlotinib, whereas EGFR-mutant NSCLC cells vir-
tually exhibit epithelial phenotypes.15
In this study, we developed resistant cells from the
erlotinib-sensitive HCC4006 cell line, which harbors an
EGFR mutation. Analyses of acquired resistance mechanisms
led to the identification of epithelial to mesenchymal transi-
tion (EMT) features in cells exhibiting acquired resistance.
This is the first report indicating the involvement of EMT in
acquired resistance to EGFR-TKIs in erlotinib sensitive
EGFR-mutant lung cancers.
MATERIALS AND METHODS
Cell Lines and Reagents
The EGFR mutant human lung adenocarcinoma cell
line HCC4006 (del L747_E749, A750P) was the kind gift
of Dr. Adi F. Gazdar. HCC4006 cells were cultured in
RPMI1640 medium supplemented with 5% fetal bovine se-
rum (FBS) and 1 antibiotic–antimycotic solution (Invitro-
gen, Carlsbad, CA) at 37°C in a humidified incubator with
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5% CO2. The identity of the HCC4006 cells was confirmed at
the beginning of this study by the identification of the rare
type of EGFR deletion mutation in this cell line.
Erlotinib was kindly provided by Hoffmann-La Roche,
Inc. (Nutley, NJ). The selective MET inhibitor PHA-665,752
and the selective transforming growth factor beta (TGFbeta)
receptor I inhibitor SD208 were purchased from Tocris Bio-
science (Ellisville, MO) and Sigma-Aldrich Co. (St. Louis,
MO), respectively. The allosteric MEK inhibitor PD0325901
and AKT 1/2 kinase inhibitor were purchased from Wako
(Osaka, Japan). The histone deacetylase (HDAC) inhibitor
MS-275 was purchased from Selleck Chemicals (Houston,
TX). Human TGFbeta 1 was purchased from R&D Systems
(Minneapolis, MN).
Generation of In Vitro Erlotinib-Resistant
HCC4006 Cells
Erlotinib-resistant HCC4006 (HCC4006ER) cells were
developed by chronic, repeated exposure to increasing concen-
trations of erlotinib, from 20 nM to 2 M, as described previ-
ously.7 The concentration of erlotinib was increased stepwise
when the cells resumed proliferation, similar to the pattern in
untreated parental cells. Two clones (HCC4006ER4 and ER5)
were isolated by limiting dilution.
Cell Proliferation Assay
Cell proliferation was measured using TetraColor ONE
(Seikagaku-kogyo, Tokyo, Japan), according to the manufac-
turer’s instructions. Briefly, tumor cells (3 103) were plated
into each well of 96-well flat-bottomed plates and were
grown in RPMI1640 containing 5% FBS. Twenty-four hours
later, dimethyl sulfoxide (DMSO), erlotinib, PHA-665,752,
PD0325901, AKT 1/2 kinase inhibitor, SD208, or a combi-
nation of these drugs was added to the indicated drug con-
centration, and cells were incubated for an additional 72
hours. MS-275 was added at the initial cell plating. A color-
imetric assay was performed after addition of 10 l Tetra-
Color ONE to each well, and the plates were incubated at
37°C for 1 hour. Absorbance at 450 nm was read using a
multiplate reader. Percent growth was determined relative to
DMSO-treated controls.
Preparation of DNA and RNA
Genomic DNA was extracted using a FastPure DNA
Kit (Takara Bio, Otsu, Japan), according to the manufacturer’s
protocol. Total RNA was prepared using a mirVana miRNA
Isolation Kit (Qiagen, Valencia, CA), according to the man-
ufacturer’s protocol. Random-primed, first-strand comple-
mentary DNA was synthesized from total RNA using Super-
script II (Invitrogen), according to the manufacturer’s
instructions.
Mutation Analysis
Mutation analysis of exons 18 to 21 of the EGFR gene
and exons 1 to 2 of the KRAS gene was performed by direct
sequencing after one-step reverse transcription polymerase
chain reaction (RT-PCR) from total RNA using the Qiagen
OneStep Reverse Transcription PCR Kit (Qiagen), as re-
ported previously.16
Gene Copy Number Analysis
The number of copies of the MET gene relative to a
LINE-1 repetitive element was measured using quantitative
real-time PCR using the SYBR Green Method (Power SYBR
Green PCR Master Mix; Qiagen) on an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA) as described previously.7,17 Normal genomic DNA
was used as a standard sample.
Phospho-Receptor Tyrosine Kinase Array
Analysis
A Human Phospho-RTK Array Kit (R&D Systems) was
used to measure the relative level of tyrosine phosphorylation of
42 distinct receptor tyrosine kinases (RTKs). HCC4006 and
HCC4006ER5 cells were cultured in RPMI1640 containing
5% FBS until subconfluency. The media was changed to 5%
FBS containing DMSO or 2 M erlotinib, respectively, for
24 hours, and the cells were lysed with NP-40 lysis buffer,
according to the manufacturer’s protocol. The arrays were
blocked with blocking buffer and incubated with 450 g of
cell lysate overnight at 4°C. The arrays were washed, incu-
bated with a horseradish-peroxidase-conjugated phospho-
tyrosine detection antibody, treated with ECL solution (GE
Healthcare, Buckinghamshire, UK), and exposed to film.
Phospho-Kinase Array Analysis
A Human Phospho-kinase Array Kit (R&D Systems) was
used to measure the relative level of phosphorylation of 46
distinct intracellular kinases. HCC4006 and HCC4006ER5 cells
were cultured in RPMI1640 containing 5% FBS until subcon-
fluency. The media was changed to 5% FBS containing 2 M
erlotinib for 8 hours, and the cells were lysed using the lysis
buffer provided. The arrays were blocked with blocking
buffer and incubated with 450 g of cell lysate overnight at
4°C. The arrays were washed and incubated with a biotinyl-
ated antibody for 2 hours. The arrays were washed again,
incubated with a streptavidin–horseradish-peroxidase-conju-
gated detection antibody, treated with ECL solution, and
exposed to film.
Antibodies and Western Blot Analysis
Antiphospho-EGFR, anti-EGFR, antiphospho-insulin-
like growth factor I receptor (IGF-IR), anti-IGF-IR, antiphos-
pho-Akt, anti-Akt, antiphospho-extracellular signal-regulated
kinase (ERK), anti-ERK, anti-E-cadherin, antivimentin, anti-
SMAD2/3, antiphospho-SMAD2, and antiphospho-SMAD3
antibodies were purchased from Cell Signaling Technology
(Beverly, MA). The antibeta actin antibody was purchased
from Sigma (St Louis, MO). Anti-SMAD4, anti-TGFbeta-
receptor I, and anti-TGFbeta-receptor II antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The preparation of total cell lysates and immunoblot-
ting was performed as described previously. Briefly, cells
were cultured until subconfluency, and media was changed to
5% FBS containing DMSO or the indicated concentration of
the various drugs. After 8 hours, cells were rinsed with
phosphate-buffered saline, lysed in sodium dodecyl sulfate
sample buffer, and homogenized. Total cell lysate (30 g)
was subjected to sodium dodecyl sulfate polyacrylamide gel
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electrophoresis and transferred to Immobilon-P polyvi-
nylidene difluoride membranes (Millipore, Bedford, MA).
After blocking with 5% nonfat dry milk, membranes were
incubated with primary antibodies, washed with phosphate-
buffered saline, reacted with secondary antibodies, treated
with ECL solution, and exposed to film.
EGFR siRNA Transfection
HCC4006 and HCC4006ER5 cells were reverse trans-
fected using scrambled siRNA or one of two kinds of spe-
cific, validated siRNAs for EGFR (Applied Biosystems)
using the Lipofectamine RNAiMAX transfection reagent (In-
vitrogen), according to the manufacturer’s instructions.
Microarray Analysis
Agilent human whole-genome microarray analyses
were performed to assess differences in gene expression
between HCC4006 and HCC4006ER5 cells. Each of the cell
lines was cultured in RPMI1640 containing 5% FBS until
subconfluency. The media was changed to 5% FBS contain-
ing 2 M erlotinib for 8 hours, and total RNA was isolated.
RNA quality was confirmed using the Agilent 2000 Bioana-
lyzer, and 200 ng of each total RNA was used for probe
generation and hybridization. HCC4006ER5 cells (labeled
with cyanine-5) were characterized by comparison with
HCC4006 (labeled with cyanine-3) cells on a single slide.
The microarray slide was read using an Agilent Scanner,
and the Agilent Feature Extraction software was used to
calculate gene expression values. We performed a gene-set
enrichment analysis (GSEA) to identify gene-signature-
based differences.18
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR was performed on first-
strand complementary DNA using TaqMan probes and the
TaqMan Universal PCR Master Mix (Applied Biosystems).
TaqMan probes for EGFR, human EGF receptor 2 (HER2),
HER3, HER4, and phosphatase and tensin homolog (PTEN)
were purchased from Applied Biosystems, and the amplifi-
cation was performed on an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems), according to the
manufacturer’s instructions. Quantification was performed in
triplicate, and the level of expression of 18S rRNA was used
as an internal control.
RESULTS
In Vitro Erlotinib-Resistant HCC4006 Cells Did
Not Harbor Known TKI-Resistance Mechanisms
First, we generated two HCC4006 cell clones that were
resistant to erlotinib (designated as HCC4006ER4 and ER5)
by growing cells in increasing concentrations of erlotinib (to
a final concentration of 2 M) for up to 4 months in vitro, as
FIGURE 1. Establishment of
HCC4006ER cells by chronic, re-
peated exposure to increasing con-
centrations of erlotinib. A,
HCC4006ER cells were resistant to
erlotinib. HCC4006 or HCC4006ER5
cells were incubated for 24 hours
and an additional 72 hours with the
indicated concentrations of erlo-
tinib, and cell growth was assessed.
B, Analysis of activated receptor
tyrosine kinases (RTKs) using a Hu-
man Phospho-RTK Array Kit. Whole-
cell extracts from HCC4006 and
HCC4006ER5 cells exposed for 24
hours to the indicated drugs were
incubated with the arrays, and
phosphorylation status was deter-
mined. Each RTK was spotted in du-
plicate, and the pairs of dots in
each corner are positive controls. C,
Morphological differences observed
between HCC4006 and
HCC4006ER5 cells.
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described previously.7,19 HCC4006ER cells were more than
500 times more resistant to erlotinib (and to gefitinib, data not
shown) compared with the parental HCC4006 cells (Figure
1A). We found remarkable differences between HCC4006ER
cells and parental HCC4006 cells regarding their appearance.
The morphological changes observed in the resistant cells
included loss of intercellular connection and loss of polarity
(Figure 1B, left and right panels).
First, we extracted RNA and DNA from HCC4006ER4
and ER5 cells and performed analyses of mutation, amplifi-
cation, or gene expression for the various candidate genes.
Mutation analyses revealed that neither secondary mutations
in exons 18 to 21 of the EGFR gene (including T790M) nor
mutations in exons 1 to 2 of the KRAS gene were detected in
the resistant cells, although the resistant cells preserved
EGFR deletion mutation in exon 19. The MET gene copy
number in the resistant cells, as assessed using quantitative
real-time PCR, was identical to that observed in the parental
cells and to that of normal DNA. The expression of the PTEN
gene in the resistant cells, as assessed using quantitative
real-time RT-PCR, was also identical to that found in the
parental cells. In addition, the MET inhibitor PHA-665,752
did not restore erlotinib sensitivity in resistant cells.
Therefore, we analyzed the activation of RTKs compre-
hensively using a phospho-RTK array. Although HCC4006 cells
exhibited activation of HER family members and MET in the
absence of erlotinib (Figure 1C, top), phospho-RTK array
analysis of HCC4006ER5 cells showed a remarkable de-
crease in the phosphorylation of EGFR, without activation of
any other RTKs (Figure 1C, bottom).
In addition, we analyzed the expression of EGFR and
IGF-IR, the activation of which reportedly causes acquired
resistance to gefitinib in A431 cells,8 using immunoblot analysis
(Figure 2A). The basal EGFR activity in HCC4006ER5 cells
was lower, compared with that observed in parental cells. In
addition, erlotinib inhibited the phosphorylation of EGFR effec-
tively in both cell lines. In contrast, the level of phosphorylation
of IGF-IR was slightly increased in HCC4006 parental cells in
the presence of 1 M erlotinib; however, phospho-IGF-IR was
not detected in HCC4006ER5 cells, regardless of the concen-
tration of erlotinib.
HCC4006ER5 Cells Lost Dependency for EGFR
Next, we analyzed whether HCC4006ER5 cells re-
tained dependency for EGFR using two kinds of validated
siRNAs (Figure 2C). Although siRNA-mediated knockdown
FIGURE 2. Analyses of intracellular signaling
pathways and epidermal growth factor receptor
(EGFR) dependency in HCC4006 and
HCC4006ER5 cells. A, Cells were incubated for 8
hours with the indicated concentrations of erlo-
tinib, and changes in EGFR- or insulin-like growth
factor I receptor (IGF-IR)-related signals were ana-
lyzed using Western blotting. B, Analysis of acti-
vated intracellular kinases using the Human Phos-
pho-kinase Array Kit. Whole-cell extracts from
HCC4006 and HCC4006ER5 cells exposed to 2
M erlotinib for 8 hours were incubated with the
arrays, and phosphorylation status was deter-
mined. Each kinase was spotted in duplicate and
the pairs of dots in each corner (with the excep-
tion of the right-lower corner) are positive
controls. C, Confirmation of EGFR knockdown us-
ing two different siRNAs. HCC4006ER5 cells were
reverse-transfected with the indicated siRNA, incu-
bated for 72 hours, and EGFR-related signals were
analyzed using Western blotting. D, HCC4006ER
cells were EGFR independent. HCC4006 or
HCC4006ER5 cells were reverse-transfected with
control siRNA or EGFR2 siRNA, incubated for 24
hours and an additional 48 hours with the indi-
cated concentrations of erlotinib (Er.), and cell
growth was assessed.
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of EGFR suppressed the survival of the parental cells effec-
tively to a level that was similar to that obtained after
erlotinib addition, knockdown of EGFR did not affect cell
viability in HCC4006ER5 cells irrespective of the presence of
erlotinib (Figure 2D).
HCC4006ER5 Cells Maintained the Activity of
ERK and Akt in the Presence of Erlotinib
Next, we analyzed the activation of RTK downstream
molecules using immunoblot analysis (Figure 2A) and iden-
tified that the activity of ERK and Akt was maintained in
HCC4006ER5 cells, but not in parental cells, in the presence
of erlotinib. This was consistent with the result that siRNA-
mediated EGFR knockdown did not affect the phosphoryla-
tion of ERK and Akt in HCC4006ER5 cells (Figure 2C). In
addition, we analyzed the differences in intracellular kinase
activation comprehensively using a phospho-kinase array;
however, we just confirmed the phosphorylation of ERK and
Akt in HCC4006ER5 cells (Figure 2B).
Therefore, we examined whether the ERK inhibitor
(PD0325901), the Akt inhibitor (AKT 1/2 Kinase Inhibitor), or
the combination of both drugs can suppress the growth of
HCC4006ER5 cells. HCC4006 parental cells and HCC4006ER5
cells both showed moderate sensitivity to PD0325901
(Figure 3A); however, HCC4006ER5 cells were more
resistant to Akt inhibition compared with parental cells
(Figure 3B). Combination of 1 M of each drugs effec-
tively inhibited the growth of HCC4006 parental cells but
not of the resistant cells (Figure 3C), although both drugs
worked well in both cell lines (Figure 3D).
Gene-Expression Profiling for the Identification
of Molecules and Pathways Involved in
Acquired Resistance to Erlotinib in
HCC4006ER5 Cells
We performed a DNA microarray analysis to identify
genes that are overexpressed or suppressed in HCC4006ER5
cells compared with parental cells. The evaluation of the
expression levels of RTKs led to the identification of a
decrease in the expression of HER family members in
HCC4006ER5 cells (Figure 4A), which was confirmed using
FIGURE 3. Growth inhibitory effects of the
MEK inhibitor and/or the Akt inhibitor. A–C,
HCC4006 or HCC4006ER5 cells were incu-
bated for 24 hours and an additional 72
hours with indicated concentrations (nM) of
the MEK inhibitor PD0325901 (PD; A), with
the Akt inhibitor AKT 1/2 Kinase Inhibitor
(AKT; B), or with the combination (Comb)
of both drugs (C), and cell growth was as-
sessed. D, Cells were incubated for 8 hours
with 2 M of the indicated drug(s), and
activations of Akt or ERK were analyzed us-
ing Western blotting.
Suda et al. Journal of Thoracic Oncology • Volume 6, Number 7, July 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1156
quantitative real-time RT-PCR. In contrast, we observed an
increase in the expression of several RTKs in HCC4006ER5
cells (e.g., fibroblast growth factor receptor 1, EPH receptor
A2, platelet-derived growth factor receptor, alpha polypep-
tide [PDGFRA], PDGFRB, KIT, and chemokine [C-X-C
motif] receptor 4 [CXCR4]); however, most of these mole-
cules were included in the phospho-RTK array analysis
described earlier. We performed siRNA-mediated knock-
down of CXCR4, which was not included in the phospho-
RTK array; however, the suppression of CXCR4 did not
restore erlotinib sensitivity in HCC4006ER5 cells (data not
shown). We also found 16 times increase in the expression of
ATP-binding cassette, subfamily B (MDR/TAP), member 1
(ABCB1) in HCC4006ER5 cells. However, simple involve-
ment of multidrug resistance pumps for acquired resistance
mechanism in HCC4006ER cells would not be possible,
because HCC4006ER cells lost EGFR dependency (Figures
2C, D) and erlotinib effectively inhibited the phosphorylation
of EGFR in HCC4006ER cells (Figure 2A).
The most notable gene expression feature observed in
HCC4006ER5 cells was the down-regulation (2.7  103
times) of E-cadherin, which is a marker of the epithelial
phenotype. Conversely, markers of the mesenchymal phe-
notype were up-regulated in HCC4006ER5 cells: vimentin,
2.2 times; fibronectin, 3.0 times; and zinc finger E-box
binding homeobox 1(ZEB1), 4.4 times. Loss of E-cadherin
expression was confirmed using immunoblotting analysis
(Figure 4B). These expression features and morphological
changes, the loss of intercellular connection, and the loss
of polarity were consistent with the presence of EMT in
HCC4006ER5 cells.
Microarray data were ranked according to the ratio of the
levels of expression detected in HCC4006ER5 cells to that
observed in HCC4006 cells. Subsequently, we performed
GSEA, which is a gene-expression profiling analytical method
that was developed recently.18 The results showed that gene sets
involved in the TGFbeta signaling pathway were up-regulated in
HCC4006ER5 cells (Figure 4C). This was consistent with the
FIGURE 4. Epithelial to mesenchy-
mal transition (EMT) and elevation
of transforming growth factor beta
(TGFbeta)-related signaling in
HCC4006ER5 cells. A, Relative gene
expression levels of several receptor
tyrosine kinases (RTKs) determined
using a gene expression array. HER
family members were completely
down-regulated in HCC4006ER5
cells. B, Loss of E-cadherin expres-
sion and up-regulation of vimentin
in HCC4006ER5 cells, as assessed
using Western blotting. C, Elevation
of TGFbeta-related signaling in
HCC4006ER5 cells, as assessed us-
ing gene-set enrichment analysis
(GSEA). D, Downstream signaling of
TGFbeta in HCC4006 and
HCC4006ER5 cells was identified
using Western blotting.
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EMT feature observed in HCC4006ER5 cells, as TGFbeta is a
ligand that induces EMT.20 Next, we analyzed the TGFbeta
receptors I and II, as well as downstream molecules, using
immunoblot analysis. However, the only obvious difference
detected was the decrease in the phosphorylation of SMAD2 in
HCC4006ER5 cells (Figure 4D). In addition, SD208, which
is a selective TGFbeta receptor I kinase inhibitor, did not
restore remarkable erlotinib sensitivity in HCC4006ER5
cells (Figure 5A).
The HDAC Inhibitor Restored E-Cadherin
Expression and Moderate Erlotinib Sensitivity
in HCC4006ER5 Cells
Therefore, we analyzed whether the restoration of
E-cadherin sensitize HCC4006ER5 cells to erlotinib. Refer-
ring to the previous report, we treated HCC4006ER5 cells
with the HDAC inhibitor, MS-275, and identified that
E-cadherin was restored after 72 hours treatment of 1 M
MS-275 (Figure 5B). Interestingly, MS-275 treatment
induced moderate suppression of Akt and ERK activity in
HCC4006ER5 cells in response to erlotinib (Figure 5B).
In addition, we identified that the combination of 1 M
MS-275 and erlotinib moderately inhibited the growth of
HCC4006ER5 cells (Figure 5C).
Addition of TGFbeta Mimicked EMT and
Acquired Resistance in HCC4006 Cells
To examine the involvement of EMT in acquired re-
sistance in HCC4006 cells, we cultured these cells in the
presence of 2 ng/ml of TGFbeta, a ligand that induces EMT,
for 2 weeks. As shown in Figure 6A, HCC4006/TGFbeta cells
acquired morphological changes that were similar to those of
HCC4006ER5 cells. Analyses of response to erlotinib re-
vealed that HCC4006/TGFbeta cells were moderately resis-
tant to erlotinib compared with parental cells and that resis-
tance was restored by the addition of 5 M SD208 (Figure
6B). Immunoblot analyses showed an increase in the phos-
phorylation of SMAD2 and down-regulation of E-cadherin in
HCC4006/TGFbeta cells, with maintenance of the level of
phosphorylation of ERK and Akt in the presence of erlotinib
(Figure 6C). The removal of TGF-beta for 2 weeks canceled
the morphological changes and resistance to erlotinib ob-
served in HCC4006/TGFbeta cells.
DISCUSSION
EMT is a process in which epithelial cells that are
organized, polarized, and tightly connected transdifferentiate
into disorganized mesenchymal cells, which is accompanied
FIGURE 5. The histone deacetylase (HDAC) in-
hibitor but not the transforming growth factor
beta (TGFbeta) inhibitor restored moderate sensi-
tivity to erlotinib in HCC4006ER5 cells. A, SD208
did not restore remarkable erlotinib (Er.) sensitivity
in HCC4006ER5 cells. HCC4006ER5 cells were in-
cubated for 24 hours and an additional 72 hours
with the indicated concentrations (nM) of erlo-
tinib with/without 5 M SD208, and cell growth
was determined. B, Expression of E-cadherin and
downstream signaling of EGFR in HCC4006 cells
and in HCC4006ER5 cells treated with/without
MS-275 and erlotinib were assessed using Western
blotting. C, MS-275 restored moderate erlotinib
sensitivity in HCC4006ER5 cells. HCC4006ER5
cells were incubated with/without 1 M MS-275
for 24 hours and an additional 72 hours with indi-
cated concentration of erlotinib (nM) with/with-
out MS-275, and cell growth was determined.
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by changes in the expression of molecular marker proteins
(e.g., down-regulation of E-cadherin and up-regulation of
vimentin, fibronectin, and N-cadherin).21,22 The relationship
between EGFR-TKI sensitivity and changes from mesenchy-
mal to epithelial status, or vice versa, has been reported in
NSCLC without EGFR mutations.12,23,24 Witta et al.12 re-
ported that transfection of E-cadherin into H157 cells (a
KRAS mutant cells with a mesenchymal phenotype), or pre-
treatment with MS-275, which induces the expression of
E-cadherin, increased their sensitivity to gefitinib. In contrast,
Thomson et al.23 reported that TGFbeta-treated H358 cells (a
KRAS mutant cells with an epithelial phenotype) acquired a
mesenchymal phenotype and lost their moderate erlotinib
sensitivity. In addition, Rho et al.24 generated a cell line that
was more resistant to gefitinib from A549 cells (KRAS mu-
tant), which are moderately resistant to gefitinib, and showed
that EMT occurred in A549 gefitinib-resistant cells. Although
these reports dealt with NSCLC without EGFR mutations, in
this study we showed that an EGFR-mutant NSCLC cell line
with acquired resistance to erlotinib also exhibited an EMT
phenotype. Although our findings are the same with above
previous studies, this study has much significance because
EGFR-TKIs are very effective in patients with lung cancer
with EGFR mutations but not in patients with wild-type
EGFR (including those with KRAS mutations).
In this study, we found significantly increased expres-
sion of gene set that is related to the TGFbeta signaling
pathway, as assessed using GSEA. Although very recent
study by Yao et al.25 has shown that erlotinib hyper-resistant
cells established from H1650 cells (EGFR mutant, but erlo-
tinib resistant due to PTEN deletion) displayed mesenchymal-
like features and harbored increased TGFbeta-dependent
IL-6 secretion, we failed to identify further evidence that
showed the involvement of TGFbeta in acquired resistance
to erlotinib. In addition, the expression level of IL-6 in
HCC4006ER5 cells in this study was identical to that
observed in parental cells, contrasting with the study by
Yao et al. Because TGFbeta is a inducer of EMT, we
suggested that unidentified cause(s), other than TGFbeta,
increased expression of genes similar to those induced by
TGFbeta addition and eventually conferred EMT-like phe-
notype on HCC4006ER cells.
HCC4006ER5 cells were also resistant to EGFR knock-
down by siRNA transfection. This was in contrast with what
was observed in parental HCC4006 cells, which indicates that
HCC4006ER5 cells lost “EGFR addiction.” This suggests the
involvement of the activation of other oncoprotein(s) or other
oncogenic pathway(s). First, we ruled out the involvement of
MET7 or IGF-IR,8 which cause EGFR-TKI resistance in
NSCLC. Down-regulation of PTEN also reportedly cause
erlotinib primary resistance26 or acquired resistance to cetux-
imab27 or gefitinib,28 respectively, in EGFR-mutant lung
cancer cell lines. Nevertheless, the level of expression of
PTEN in HCC4006ER cells was identical to that observed in
parental cells. The involvement of autocrined hepatocyte
growth factor was also ruled out, as the MET inhibitor did not
restore erlotinib sensitivity in HCC4006ER cells. In addition,
we did not identify any other “targetable oncoprotein” can-
didates in HCC4006ER5 cells (other than EGFR) using
phospho-protein (RTK and intracellular kinase) array analy-
ses or a gene expression assay. These results suggest that
mesenchymal status, and not a specific oncogenic activated
protein, confers resistance to erlotinib in HCC4006 cells.
Although the “primary change” observed in HCC4006ER
cells was not clear, we found that the HDAC inhibitor,
MS-275, restored E-cadherin expression and moderate erlo-
FIGURE 6. Transforming growth factor beta
(TGFbeta) treatment reduced erlotinib sensitivity
in HCC4006 cells. A, Morphological changes ob-
served in HCC4006 cells after treatment with 2
ng/ml TGFbeta for 2 weeks. B, TGFbeta induced
erlotinib resistance and SD208 restored sensitivity
in HCC4006 cells. HCC4006 cells or HCC4006
cells treated with TGFbeta for 2 weeks were incu-
bated for 24 hours and an additional 72 hours
with the indicated concentrations of erlotinib (Er.)
with/without 5 M SD208, and cell growth was
determined. C, Downstream signaling of TGFbeta
and EGFR in HCC4006 cells and in HCC4006 cells
treated with TGFbeta for 2 weeks, as assessed us-
ing Western blotting.
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tinib sensitivity in HCC4006ER5 cells. We used MS-275
because this drug was used in the similar experiments12 and
was reported to reverse EMT in vivo.29 Although the addition
of MS-275 might confer combined effects rather than simple
restoration of E-cadherin, our results would have clinical
significance because HDAC inhibitors, including MS-275,
are now under clinical development. Combination therapy
for an HDAC inhibitor and erlotinib may be effective
against tumors with acquired resistance to gefitinib or
erlotinib by EMT.
The involvement of EMT in acquired resistance to
gefitinib or erlotinib in clinically treated patients is unclear.
However, it is also true that many of the resistance mecha-
nisms identified using in vitro analyses have been found in
clinically TKI-refractory samples. Moreover, a recent report
that analyzed the expression profiles of epithelial and
mesenchymal protein markers suggests the involvement of
EMT in acquired resistance to gefitinib in EGFR-mutant
lung cancer patients; although the interpretations included
in the report had some weaknesses as discussed by the
authors.30
In conclusion, our results suggest a role for EMT in
acquired resistance to EGFR-TKIs in NSCLCs with EGFR
mutations. The results of phase III studies reported re-
cently31,32 showed that many patients with NSCLC with
EGFR mutations should be treated with EGFR-TKIs in the
early phase of treatment. It may be important to consider the
influence of EMT in the development of treatments for
EGFR-TKI acquired resistance.
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